Genetic association studies often collect information on secondary phenotypes related to the primary disease status. In many situations, the secondary phenotypes are only measured in subjects with the disease condition. It would be advantageous to model the primary trait and the secondary phenotype together if they share certain level of genetic heritability. We propose a family of multi-locus testing procedures to detect the composite association between a set of genetic markers and two traits (the primary trait and a secondary phenotype), in order to identify genes influencing both traits. The proposed test is derived from a random effect model with two variance components, with each presenting the genetic effect on one trait, and incorporates a model selection procedure for seeking the optimal model to represent the two sources of genetic effects. We conduct simulation studies to evaluate performance of the proposed procedure and apply the method to a genome-wide association study of prostate cancer with the Gleason score as the secondary phenotype.
Introduction
Population-based genetic association studies have been widely used for uncovering the genetic basis underlying complex diseases. Although they are typically designed to study one primary trait, information on other secondary phenotypes is often collected and is potentially valuable for the study of the primary trait. For example, besides knowing the disease status of each subject in a genetic association study of breast cancer, we might also have additional information measured on breast cancer tumor tissues, which provides more details on pathologic and molecular characteristics of the disease. Those secondary phenotypes could be helpful in identifying the disease susceptibility loci if they share certain level of genetic heritability with the primary trait.
Recently, Wu et al. 1 proposed a single-marker testing framework to assess the association between a genetic marker and two traits simultaneously in situations where the secondary phenotype is quantitative and is only measured on subjects in a particular primary trait-dependent stratum. For example, the secondary phenotype might be only available on the subjects with disease condition. The data can be collected prospectively or retrospectively with the primary trait being the disease status. Their method aims at detecting genetic markers associated with both traits and maintaining robust power even if the marker is associated with only one of traits.
Although the single-marker test has been the most commonly used approach in detecting genetic susceptibility loci, increasing evidence has suggested that multiple correlated markers within a gene could jointly influence complex diseases. 2 A multi-locus test that aggregates association evidence across multiple genetic markers in a considered gene or a genomic region may be more powerful than a single-marker test. [3] [4] [5] [6] Here, we focus on the similar setting considered by Wu et al. 1 and derive a class of multi-locus tests for the association between a set of genetic markers within a considered gene and two traits. The proposed test extends the sequence kernel association test (SKAT) 7 to a random effect model with two variance components, with each presenting a genetic effect on one trait, and incorporates a model selection procedure for seeking the optimal model to represent the two sources of genetic effects.
Many existing multi-locus tests require complete observations on the set of genetic markers. Under the current single-nucleotide polymorphism (SNP) genotyping technology, the genotype missing rate at a given SNP is very low. However, the proportion of subjects with at least one missing genotypes within a considered genomic region could still be high if the number of SNPs in the region is relatively large. Excluding those subjects with at least one missing genotype can reduce the sample size substantially and thus diminish the power of the multi-locus test. Using statistical imputation algorithms [8] [9] [10] to impute the missing genotype is a commonly used strategy to retain the sample, but it has several limitations. For example, it requires the knowledge of haplotype distribution on the studying population. Furthermore, it is known that the imputed genotype on a SNP with a relatively low minor allele frequency (MAF) is not very accurate. 11 To make the proposed test more flexible in practice, we generalize the test so that it can handle missing genotypes without resorting to imputation or removing samples.
Model
For a study with n samples, let fD i , Z i , X i , G i g be the observed data on the ith sample, with D i being the primary dichotomous trait (e.g., disease status), Z i being the secondary quantitative trait, X i being the set of covariates to be adjusted, and G i being the vector of genotypes on m genetic markers in a given gene or region. We assume that the genotype is coded as 0, 1, and 2, representing the number of minor alleles at a given marker. Other coding schemes can be dealt with similarly. We will describe our method for data sampled from a prospective cohort study, where the secondary phenotype Z i is only available on subjects with D i ¼ 1. We then extend the application of our method to a retrospective case-control study, wherein Z i is collected in cases. We refer to our method as MAPS, i.e., a Multimulti-locus Association test for a dichotomous Primary trait and a quantitative Secondary phenotype.
A random effect model for a prospective cohort study
In a prospective cohort study, we assume that the dichotomous trait D i can be modeled by the following logistic regression model given the covariates and genotypes of multiple markers within a gene 
where 0 is a zero vector of length m, and
To derive a variance component test for the null hypothesis H 0 : ¼ ¼ 0, we further assume that the genetic effects ð, Þ are random effects with E ¼ E ¼ 0, and
where I is the m Â m identity matrix and the scalars ! 0, 2 ½À1, 1, 2 ½0, 1. Here, the variance-covariance matrix is configured by three parameters under the following assumptions. First, genetic effects on the primary trait are independent and identically distributed (i.i.d.) random variables with variance . Second, genetic effects on the secondary phenotype are i.i.d. random variables with variance ð1 À Þ. Third, the genetic effects from one marker on the two traits are correlated with correlation coefficient . Fourth, the genetic effects from two markers on either the same or different traits are uncorrelated. One can see that testing the joint genetic effects on the two traits is equivalent to testing H 0 : ¼ 0. Similar to Lin, 12 we can obtain the profile log-likelihood in term of variance component parameters ð, , Þ by integrating out and
Let ð,, 2 Þ be the maximum likelihood estimates of' under the null. Define
whereŜ D (orŜ Z ) is the score S D (or S Z ) evaluated at ð,, 2 Þ. The asymptotic null distributions ofŜ D andŜ Z are multivariate normal distributions, with means 0 and estimated variance-covariance matricesŜ DD andŜ ZZ , respectively. The score for at ¼ 0 is
Note that the second term in equation (5) converges to some constant in probability for given ð, Þ, we thus can conduct a family of variance component tests based on Q , only.
For any given ð, Þ, denote p , ¼ PrðQ , !Q , Þ as the p-value of Q , evaluated at its observed valueQ , . Since ð, Þ are unknown, we propose to define the statistic for testing H 0 : ¼ 0 as
which measures the strongest evidence of the presence of association with ð, Þ tuned in proper regions. The final p-value adjusted for multiple comparisons is computed from the null distribution of T.
In the following sections, we will introduce different versions of variance component tests based on T with possible choices of the tuning parameters and . Numerical algorithms for computing the final p-value are also discussed.
The variance component test with
One simple choice of the tuning parameters in T is to set ¼ 0 and ¼ 1=2, which essentially assumes that the genetic effects distribute equally on either traits for each marker. The statistical significance can be evaluated by checking the distribution of Q 0,1=2 /Ŝ T DŜ D þŜ T ZŜ Z , which follows a mixture of chi-square distributions under the null. Several existing algorithms are available for computing the distribution function of Q 0,1=2 , thus the p-value can be calculated accurately. [13] [14] [15] This test is referred as MAPS 0,1/2 .
The variance component test with q ¼ 0
A more flexible approach is to fix ¼ 0 while allowing to vary in ½0, 1. The test statistic becomes T ¼ min 2½0,1 p 0, . In practice, we can choose at the grids fk=20 : k ¼ 0, . . . , 20g. For any given
Notice that S D is asymptotically independent with S Z since
@@ T ¼ 0, the final p-value of T defined can be computed explicitly by an one-dimensional numerical integration algorithm. The details are given in Appendix 1. This test is referred as MAPS 0 .
The variance component test with variable o and i
In real application, we usually do not have any prior knowledge on the values of and . A robust approach is to maximize the association evidence over ð, Þ 2 ½À1, 1 Â ½0, 1, i.e., we define the statistic as
To assess the significance of T, we can generate the scores ofŜ D andŜ Z under the null via the direct simulation approach. 16 The final p-value of T is then estimated through the computationally efficient minP algorithm. 17 We refer this optimal test as MAPS opt . As a special case, the MAPS opt test with fixed to be 1/2, and tuned in ½À1, 1, is referred as MAPS cor . The p-value of MAPS cor can be computed similarly as MAPS opt .
Existing approaches
There are several alternative approaches that are applicable to the setting considered in this paper. The SKAT has been successfully applied in identifying genetic regions associated with complex diseases. 7 In the following discussion, the SKAT tests applied to either the dichotomous or quantitative trait are referred as SKAT D and SKAT Z , respectively. In addition, the standard likelihood ratio test (LRT), which compares the additive model consisting of all the genetic markers with the null model, can be applied to each trait separately, leading to two tests LRT D and LRT Z , respectively. These two tests may loss power due to large degree-of-freedoms. Finally, we generalize the single-marker test in Wu et al. 1 to a multi-locus score test. This generalized score test follows 2 2m distribution under the null.
A random effect model for a retrospective case-control study
In a case-control study, we assume the quantitative trait Z is only observed in cases. Then the likelihood of observed data
According to Qin and Zhang, 18 the joint distribution of X i and G i satisfies
if the risk model is assumed as the logistic regression model in equation (1) . Ignoring a constant, the profile likelihood of equation (6) is equivalent to the likelihood equation (2) in a cohort study. 18 Therefore, all the tests discussed in previous subsections can be applied to case-control studies.
Missing data in multi-locus test
In the above, we have described the method assuming no missing genotypes at any considered genetic markers. In real application, we might have a substantial proportion of individuals who have at least one missing genotype in the considered region, especially when the region consists of a large number of markers. Removing those subjects can result in substantial loss of power. To make full use of observed genotypes, we propose to use following modified score statistics defined on observed genotypes.
Without loss of generality, we consider the generalized linear model
@@ T . A superscript j on these defined term means only individuals in S j are used. For example, ' j j is the score of j defined on S j . In contrast, the score of can be defined on either S (i.e., ' ) or S j (i.e., ' j ). Similarly, superscript jk means individuals in S j \ S k are used. Let ð j ,^ j Þ be the maximum likelihood estimates of ð, Þ using S j under the null.
Statistics denoted with accent b is assessed at ð,^ Þ (e.g.,'
We show in the Appendix 1 that, under the assumption of missing at complete randomness, the modified scorê 
, where n jk is the sample size of S j \ S k . ReplacingŜ D andŜ Z in equation (4) by the modified score' allows the proposed method to handle data with missing genotypes, where ð jk Þ mÂm is used as the modified variance-covariance matrix in the direct simulation for the evaluation of the p-value.
In this procedure, the score' is estimated using information on n jk subjects, which is very close to the original total sample size if the proportion of missing genotype at each marker is low. Thus, this strategy is much more efficient than the one that requires the removal of subjects who have at least one missing genotypes on the set of considered markers.
This procedure is very general for handling missing genotypes in various multi-locus tests, as long as the test is based on score statistics derived from the generalized linear model. We therefore integrated this procedure into SKAT, LRT, and Wu's method, so that they can be applied to the real data application described below.
Simulation studies
We evaluated performance of the proposed variance component tests through simulation studies with genes generated under various of linkage disequilibrium (LD) structures. Similar to Wang and Elston, 19 we considered a gene consisting of 20 SNPs and a study with 500 cases and 500 controls. To generate genotypes on the 20 SNPs, we first simulated continuous random variables R ¼ ðR 1 , . . . , R 20 Þ from a multivariate normal distribution with mean zero and a variance-covariance matrix AE ¼ ð ij Þ 20Â20 , where ij ¼ r jiÀj j . By properly choosing cut-points, we then discretized R i into a three-level genotype with levels 0, 1, and 2, so that the corresponding SNP had a MAF of 0.4. The LD within this gene was controlled by the parameter r, which was chosen as either 0 or 0.6 in our simulation. We used this algorithm to generate genotypes in controls. We assumed the risk model for the primary trait (case-control status) has the following form
with the 10th and 11th SNPs conferring the risk of disease. In order to simplify the simulation, we assumed the equality of the two odds ratios. Under the given risk model, we used the weighted sampling procedure 18 to generate genotypes in cases from the following distribution
Within the stratum of D ¼ 1, the secondary quantitative trait was simulated from
with the same risk SNPs as in the risk model of the dichotomous trait. We also investigated the robustness of our method by additional simulations, in which the risk SNPs of the primary trait and the secondary trait were different. More specifically, logit PrðD ¼ 1 j GÞ ¼ G 9 þ G 10 , and Z ¼ G 11 þ G 12 þ N ð0, 1Þ.
Type I error
We evaluated the type I errors of all tests proposed in this paper, as well as the existing approaches discussed in Section 2.5. Only the results of scenario with r ¼ 0.6 are presented here. 100,000 datasets were generated under the null by setting ¼ ¼ 0, each with 500 cases and 500 controls. p-values of MAPS opt and MAPS cor were first estimated with 100,000 resampling steps. Then for those datasets with initial estimates of p-values 5 10 À4 , more accurate estimates were obtained with 1,000,000 resampling steps. Table 1 shows that all tests can properly control the type I errors at nominal levels of 0.01, 0.001, and 0.0001.
Empirical power
To compare the empirical powers of various tests under different LD structure configured by r, we chose and so that the empirical powers of LRT D and LRT Z were close to specified powers (p D , p Z ) with type I error controlled at the level of 0. In Table 2 , we summarize the empirical powers, each of which is based on 1000 simulated datasets. We can see from the table that, when the same SNPs in a causal gene influence both traits, MAPS opt and MAPS cor have the best performance among all considered tests. When the gene is associated with only one trait, MAPS 0 and MAPS opt are the most robust tests among others variance component tests, with MAPS 0 is slightly more powerful than MAPS opt due to less model selection penalty. MAPS cor is very sensitive to the underlying risk model. For example, its power is less than 1/3 of that of MAPS opt when the gene is only associated with primary trait. When two traits are influenced by different causal SNPs, the method extended from Wu et al. 1 is more powerful than other methods if all SNPs are in linkage equilibrium (r ¼ 0). When SNPs are moderately correlated (r ¼ 0.6), MAPS opt is the most robust test in discovering composite gene association.
In Figure 1 , we show the optimal ð, Þ corresponding to min , p , for each simulated dataset, in which SNPs in a gene are moderately correlated (r ¼ 0.6), and genotypes at causal SNPs shared by the two risk models are directly observed. When MAPS opt detects a significant association in practice (e.g., p < 0.01), a selected that is very close to 0 or 1 suggests that the gene under study is likely associated with only one trait.
We also compared the empirical powers among tests when the causal SNPs are not directly observed. The parameter r controlling the LD structure was set at 0.6. All other settings were similar to those used in previous simulation with full observations. The results are summarized in Table 3 . MAPS opt again appears to have the most robust performance among all considered tests, especially when the gene is associated with both traits. 
Application to a genome-wide association study of prostate cancer
We demonstrated the application of MAPS as multi-locus tests by applying them on a genome-wide association study (GWAS) of prostate cancer. We focused on 2841 controls and 4544 cases of European ancestry. 20 For each prostate cancer case, we used the Gleason score (2-10), which indicates how likely it is that a tumor will spread, as a quantitative trait. We hypothesized that there are genes influencing the mechanism underlying the development of prostate cancer, as well as how fast the tumor cells spread. By looking at the two traits jointly (i.e., prostate cancer status and Gleason score), we intend to increase our chance for detecting that type of genes. Of the SNPs genotyped using the Illumina HumanOmni2.5 BeadChip, 1,531,807 passed standard quality control criteria. 20 We extracted SNPs within 20 kb upstream and 20 kb downstream of a gene or an annotated region. The SNPs with missing rate 4 2 % or MAFs 5 2 % were excluded from the analyses. For two SNPs with LD coefficient r 2 4 0:95, the one with a smaller MAF was discarded. Both traits were adjusted for center, age, and two eigenvectors.
We will provide more detailed report on the analysis of over 20,000 genes/regions elsewhere. Here, we are interested in the 69 genes with both p-values of SKAT Z and SKAT D less than 0.05, as using tests analyzing two traits jointly are most likely to be beneficial on those genes. In Table 4 , we showed results of nine genes on which there were at least one gene-level p-value less than 0.001 by all considered two-trait joint tests. Among those, KLK3 and CLDN11 are known risk genes associated with the prostate cancer in population with European ancestry. 21, 22 IRX4 has only been identified to be associated with the risk of prostate cancer in Japanese population. 23, 24 Although the other six genes have not been reported in GWAS as genes susceptible to prostate cancer risk, overexpression of PIAS3 was known to induce apoptosis in prostate cancer cells. 25 The forest plots in Figures 2 and 3 illustrate the marginal effects from each SNP in genes LOC643201 and PIAS3 on the prostate cancer risk and the Gleason score. It shows several SNPs in either gene are associated with both traits. This is the main reason why the joint test approach appears to be more advantageous than the single-trait test approaches. We can consider those genes in Table 4 as promising candidates underlying the development of prostate cancer, although further replications are needed.
Discussion
Although genetic association studies are typically designed to study one primary trait, valuable information on other secondary phenotypes is often collected. There is a growing interest to study secondary phenotypes using already measured genotypes. Several approaches have been developed to identify genetic markers associated with The values marked in bold are known susceptibility genes of the risk of prostate cancer.
secondary phenotypes, taking account for the design of the original study. [26] [27] [28] [29] [30] The proposed method has a different goal. It analyzes the primary trait and a secondary phenotype jointly, aiming at detecting genes influencing both traits. The family of proposed tests is derived from a random effect model with two variance components, with each presenting the genetic effect on one trait. Among its various versions, we found the one that uses observed data to adaptively model the variance-covariance matrix of genetic effects has the most robust performance. We demonstrated the application of the new method by applying it to analyze a GWAS of prostate cancer and identified several promising novel regions that appeared to influence the risk and progression of prostate cancer. An R package of the proposed test is available at https://github.com/zhangh12/MAPS It has been shown that multi-locus association tests can be a valuable alternative to the commonly used singlemarker test. There are many multi-locus approaches for genetic association studies, 6, 7, 31 most of which assume that there is no missing genotype. As a result, genotype imputation is usually needed before using the multi-locus test. However, it is not a trivial task to impute the missing genotypes, and the imputation accuracy depends on the reference genome. 11 The strategy for dealing with missing genotypes proposed with our test is more flexible and easy to use, as it does not need imputing missing genotypes. Also, it uses all observed genotypes, and thus is more efficient than the strategy that requires the removal of subjects with at least one missing genotypes on the set of considered markers. This strategy is especially helpful for GWAS, where genotype missing rate at a given SNP is very low. With some modifications, this strategy can be adapted to other multi-locus tests defined by score statistics. 7, 16, 31 In our method, we use three parameters to model the variance-covariance matrix for the genetic effects on a primary trait and a secondary phenotype. To extend the method to study more than two secondary phenotypes, it is important to find an appropriate model for the variance-covariance matrix. Using too many parameters would increase the penalty for model selection and reduce efficiency of the multi-locus test. On the other hand, an oversimplified model can introduce bias into the testing procedure. Further investigations are needed to extend the proposed method to study more secondary phenotypes.
